Advertisement
Advertisement

BTAI

BTAI logo

BioXcel Therapeutics, Inc. Common Stock

1.31
USD
Sponsored
+0.05
+3.97%
Jun 24, 15:59 UTC -4
Closed
exchange

After-Market

1.31

0.00
+0.15%

BTAI Earnings Reports

Positive Surprise Ratio

BTAI beat 16 of 33 last estimates.

48%

Next Report

Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
$261.80K
/
-$0.52
Implied change from Q1 26 (Revenue/ EPS)
+27.09%
/
-3.70%
Implied change from Q2 25 (Revenue/ EPS)
+118.17%
/
-78.78%

BioXcel Therapeutics, Inc. Common Stock earnings per share and revenue

On May 15, 2026, BTAI reported earnings of -0.54 USD per share (EPS) for Q1 26, beating the estimate of -0.84 USD, resulting in a 35.72% surprise. Revenue reached 206.00 thousand, compared to an expected 356.24 thousand, with a -42.17% difference. The market reacted with a -5.79% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of -0.52 USD, with revenue projected to reach 261.80 thousand USD, implying an decrease of -3.70% EPS, and increase of 27.09% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Vistagen Therapeutics, Inc. Common Stock
Report Date
Jun 15, 2026 For Q4 26
Estimate
-$0.34
Actual
-$0.37
Surprise
-7.75%
logo
enGene Therapeutics Inc. Common Stock
Report Date
Jun 15, 2026 For Q2 26
Estimate
-$0.47
Actual
-$0.43
Surprise
+10.32%
logo
Prenetics Global Limited Class A Ordinary Share
Report Date
Jun 10, 2026 For Q1 26
Estimate
-$1.10
Actual
-$1.61
Surprise
-45.36%
logo
Anixa Biosciences, Inc.
Report Date
Jun 10, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.07
Surprise
+21.61%
FAQ
For Q1 2026, BioXcel Therapeutics, Inc. Common Stock reported EPS of -$0.54, beating estimates by 35.72%, and revenue of $206.00K, -42.17% below expectations.
The stock price moved down -5.79%, changed from $1.21 before the earnings release to $1.14 the day after.
The next earning report is scheduled for Aug 10, 2026.
Based on 6 analysts, BioXcel Therapeutics, Inc. Common Stock is expected to report EPS of -$0.52 and revenue of $261.80K for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement